Drug Delivery System
Online ISSN : 1881-2732
Print ISSN : 0913-5006
ISSN-L : 0913-5006
[Feature articles] “Controlled release-driven clinical benefits and next orientation” Editor:Shinji Sakuma
The role of long-acting injection in schizophrenia treatment and future challenges
Masakazu HatanoHiroyuki KameiNakao Iwata
Author information
JOURNAL FREE ACCESS

2016 Volume 31 Issue 3 Pages 186-193

Details
Abstract
Long-acting injection is a controlled release agent, which was designed that stable blood concentration is provided by giving it once in two to four weeks. Schizophrenia treatment is essential to long-term medication. So, LAI is one of the useful therapeutic strategies. Although traditional LAI had the strong negative impression to be forcibly used for the patients with the refusing medication and the lack of insight into disease, LAI of second-generation antipsychotics are expected to maintenance therapy for the outpatients with Schizophrenia. While psychiatric medical care is shifting from hospitalization to outpatient department, and a role of LAI is important in social rehabilitation. Here, we outline to the clinical importance, characteristic, and future challenge of LAI in psychiatric treatment.
Content from these authors
© 2016 The Japan Society of Drug Delivery System
Previous article Next article
feedback
Top